Product Categories
| Country: | China |
|---|---|
| Tel: | 400-6206333 |
| Mobile: | 13167063860 |
| E-mail: | market@aladdin-e.com |
| QQ: | 3004013043 |
| Skype: | Chat Now! |
| Product Name | MF | CAS | Details |
|---|
| Telazorlimab (anti-TNFRSF4) | 2126777-87-3 | Details |
| Dysprosium(III) trifluoromethanesulfonate | C3DyF9O9S3 | 139177-62-1 | Details |
| Dehydroepiandrosterone sulfate | C19H28O5S | 651-48-9 | Details |
| Bimagrumab (anti-ACVR2B) | 1356922-05-8 | Details |
| Bis(hexamethylene)triamine | C12H29N3 | 143-23-7 | Details |
| Xentuzumab (anti-IGF1) | 1417158-65-6 | Details |
| Meropenem-d6 | C17H25N3O5S | 1133424-00-6 | Details |
| Ranibizumab (anti-VEGFA) | C11H12N2O2 | 347396-82-1 | Details |
| Ethyl 2-oxo-4-phenylbutyrate | C12H14O3 | 64920-29-2 | Details |
| IDO-IN-13 | C26H17F3N4O | 2291164-02-6 | Details |
| Benzyldiphenylphosphine | C19H17P | 7650-91-1 | Details |
| Imazapic | C14H17N3O3 | 104098-48-8 | Details |
| Nadecnemab (anti-GFRA3) | 2377679-19-9 | Details |
| Codrituzumab (anti-GPC3) | 1365267-33-9 | Details |
| 8-Azahypoxanthine | C4H3N5O | 2683-90-1 | Details |
| Tesnatilimab (anti-NKG2D) | 2242758-08-1 | Details |
| 2-(azetidin-1-yl)ethan-1-amine | C5H12N2 | 795299-77-3 | Details |
| Narsoplimab (anti-MASP2) | 2108782-45-0 | Details |
| Alizarin Yellow R sodium salt | C13H8N3NaO5 | 1718-34-9 | Details |
| Mogamulizumab (anti-CCR4) | 1159266-37-1 | Details |
| Rosmantuzumab (anti-RSPO3) | 1684393-04-1 | Details |
| Quetmolimab (anti-CX3CL1) | 2084037-83-0 | Details |
| Sirtratumab (anti-SLITRK6) | 1824663-82-2 | Details |
| Elotuzumab (anti-SLAMF7) | 915296-00-3 | Details |
| Bexmarilimab (anti-STAB1) | 2259301-27-2 | Details |
| Bivatuzumab (anti-CD44v6) | 214559-60-1 | Details |
| Urelumab (anti-TNFRSF9) | 934823-49-1 | Details |
| Apelin 17 TFA | C96H156N34O20S | 217082-57-0 | Details |
| Tamrintamab (anti-DPEP3) | 2148325-59-9 | Details |
| Cinpanemab (anti-Alpha-synuclein) | 2094516-02-4 | Details |
| Ulocuplumab (anti-CXCR4) | 1375830-34-4 | Details |
| Zansecimab (anti-ANGPT2) | 2415205-37-5 | Details |
| Vandortuzumab (anti-STEAP1) | 1557989-52-2 | Details |
| Galiximab (anti-CD80) | 357613-77-5 | Details |
| Pascolizumab (anti-IL-4) | 331243-22-2 | Details |
| Concizumab (anti-TFPI) | 1312299-39-0 | Details |
| Tarextumab (anti-NOTCH3) | 1359940-55-8 | Details |
| Tesidolumab (anti-Complement C5) | 1531594-08-7 | Details |
| Lacnotuzumab (anti-M-CSF) | 1831128-32-5 | Details |
| Ladiratuzumab (anti-SLC39A6) | 1629760-28-6 | Details |
| Tisotumab (anti-F3) | 1418628-81-5 | Details |
| Vopratelimab (anti-ICOS) | 2039148-04-2 | Details |
| Sonepcizumab (anti-Sphingosine-1-phosphate) | 1031360-18-5 | Details |
| Narnatumab (anti-RON) | 1188275-92-4 | Details |
| Ianalumab (anti-TNFRSF13C) | 1929549-92-7 | Details |
| Gemtuzumab (anti-CD33) | 220578-59-6 | Details |
| Apamistamab (anti-PTPRC) | 2097132-02-8 | Details |
| Seribantumab (anti-ERBB3) | 1334296-12-6 | Details |
| Zagotenemab (anti-Tau) | 2019133-28-7 | Details |
| KWAR23 (anti-SIRPg) | 2243227-60-1 | Details |
| Lexatumumab (anti-TNFRSF10B) | 845816-02-6 | Details |
| Ravulizumab (anti-Complement C5) | 1803171-55-2 | Details |
| Lumiliximab (anti-FceR2) | 357613-86-6 | Details |
| Fulranumab (anti-NGF) | 902141-80-4 | Details |
| Vorsetuzumab (anti-CD70) | 1165740-62-4 | Details |
| Vantictumab (anti-FZD) | 1345009-45-1 | Details |
| Indusatumab (anti-GUCY2C) | 1497400-26-6 | Details |
| Idactamab (anti-SLC1A5) | 2245205-37-0 | Details |
| Gevokizumab (anti-IL-1b) | 1129435-60-4 | Details |
| Itolizumab (anti-CD6) | 1116433-11-4 | Details |
| Vunakizumab (anti-IL-17a) | 1792181-33-9 | Details |
| Serplulimab (anti-PDCD1) | 2231029-82-4 | Details |
| Eculizumab (anti-Complement C5) | 219685-50-4 | Details |
| Sirukumab (anti-IL-6) | 1194585-53-9 | Details |
| Abelacimab(anti-Factor XI) | 2098724-83-3 | Details |
| Enoblituzumab (anti-CD276) | 1353485-38-7 | Details |
| Flanvotumab (anti-TYRP1) | 1188277-05-5 | Details |
| Bermekimab (anti-IL-1a) | 1401965-15-8 | Details |
| Inebilizumab (anti-CD19) | 1299440-37-1 | Details |
| Prezalumab (anti-B7-H2) | 1523164-68-2 | Details |
| Depatuxizumab mafodotin (anti-EGFR) | 1585973-65-4 | Details |
| Tinurilimab (anti-CEACAM6) | 2226224-30-0 | Details |
| Ocrelizumab (anti-CD20) | C19H16N2O5 | 637334-45-3 | Details |
| Ixekizumab (anti-CTLA-8) | N/A | 1143503-69-8 | Details |
| Enokizumab (anti-IL-9) | 909875-08-7 | Details |
| Emibetuzumab (anti-MET) | 1365287-97-3 | Details |
| Belimumab (anti-TNFSF13B) | 356547-88-1 | Details |
| Eldelumab (anti-CXCL10) | 946414-98-8 | Details |
| Ragifilimab (anti-TNFRSF18) | 2207590-51-8 | Details |
| Daclizumab (anti-IL2RA) | 152923-56-3 | Details |
| Rilotumumab (anti-HGF) | 872514-65-3 | Details |
| Carotuximab (anti-CD105) | 1268714-50-6 | Details |
| Brazikumab (anti-IL-23) | 1610353-18-8 | Details |
| Ontamalimab (anti-MADCAM1) | 2098790-40-8 | Details |
| Dostarlimab (anti-PD-1) | 2022215-59-2 | Details |
| Avdoralimab (anti-C5AR1) | 2226393-85-5 | Details |
| Datopotamab (anti-TROP2) | 2267989-53-5 | Details |
| Denintuzumab (anti-CD19) | 1630074-14-4 | Details |
| Guselkumab (anti-IL-23) | 1350289-85-8 | Details |
| Labetuzumab govitecan (anti-CEACAM5) | 1469876-18-3 | Details |
| Efalizumab (anti-ITGAL) | 214745-43-4 | Details |
| Oxelumab (anti-TNFSF4) | 1186098-83-8 | Details |
| Lemzoparlimab (anti-CD47) | 2377483-71-9 | Details |
| Enfortumab (anti-NECTIN4) | 1448664-46-7 | Details |
| Dinutuximab (anti-GD2) | 1363687-32-4 | Details |
| Otilimab (anti-GM-CSF) | 1638332-55-4 | Details |
| Daxdilimab (anti-ILT7) | 2245966-28-1 | Details |
| Ponsegromab (anti-GDF15) | 2368950-15-4 | Details |
| Girentuximab (anti-CA9) | 916138-87-9 | Details |
| Imaprelimab (anti-CD146) | 2014343-04-3 | Details |
| Product Total： Product Page： | ||||
| 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 | ||||